NKT cells are defined as T cells that recognize hydrophobic antigens presented by class I MHC-like molecules, including CD1d. Among CD1d-restricted NKT cells, type I and type II subsets have been noted. CD1d-restricted type I NKT cells are regarded as pro-inflammatory cells in general. On the contrary, accumulated evidence has demonstrated an anti-inflammatory property of CD1d-restricted type II NKT cells. In our earlier study using a rat model with vasculitis, we demonstrated pro-inflammatory function of CD1d-restricted type II NKT cells and identified that one such cell recognized P518-532 of rat sterol carrier protein 2 (rSCP2518-532), which appeared on vascular endothelial cells presented by CD1d. Based on this evidence, we attempted to detect human CD1d-restricted type II NKT cells in peripheral blood using hSCP2518-532, the human counterpart of rSCP2518-532, together with a CD1d tetramer in flow cytometry. First, we determined the binding of hSCP2518-532 to CD1d. Next, we detected CD3-positive hSCP2518-532-loaded CD1d (hSCP2518-532/CD1d) tetramer-binding cells in peripheral blood of healthy donors. The abundance of TGF-β-producing cells rather than TNF-αproducing cells in CD3-positive hSCP2518-532/CD1d tetramer-binding cells suggests the anti-inflammatory property of SCP2-loaded CD1d (SCP2/CD1d) tetramer-binding type II NKT cells in healthy individuals. Furthermore, we compared cytokine profile between healthy individuals and patients with vasculitis in a pilot study. Interestingly, the percentage of TGF-β-producing cells in SCP2/CD1d tetramer-binding type II NKT cells in vasculitic patients was significantly lower than that in healthy controls despite the greater number of these cells. Although further studies to clarify the mechanism and significance of this phenomenon are needed, SCP2/CD1d tetramer-binding type II NKT cells in peripheral blood should be examined in more detail to understand the pathophysiology of vasculitides in humans.
INTRODUCTION
NKT cells are defined as T cells that recognize hydrophobic antigens presented by class I MHC-like molecules, including CD1d [1] . Among CD1d-restricted NKT cells, there are two major subsets, type I and type II [2] . They are classified based on their usage of TCR and reactivity to marine sponge-derived glycolipid, α-galactocylceramide (α-GalCer). CD1d-restricted type I NKT cells are defined by the expression of a conserved TCR α-chain (Vα24-Jα18 in humans and Vα14-Jα18 in rodents) that pairs with a limited repertoire of β-chains; thus, they are usually called invariant NKT (iNKT) cells. Invariant NKT cells can bind to α-GalCer [3] . On the contrary, CD1d-restricted type II NKT cells have a more variable TCR repertoire and do not react with α-GalCer [4] . This type of cell can recognize sulfatides and hydrophobic peptides.
Difference in function between the subsets of CD1d-restricted NKT cells has been discussed. CD1d-restricted type I NKT (iNKT) cells can recognize microorganismderived glycolipids presented by CD1d and trigger both innate and acquired immune responses against the microorganism [3] . Therefore, these cells are regarded as proinflammatory cells in general. In contrast, CD1d-restricted NKT cells reactive with autologous peptides (suggestive of type II phenotype) have been shown to exhibit an antiinflammatory property in normal mice [5] .
Accumulated evidence has revealed the anti-inflammatory property of CD1drestricted type II NKT cells. Halder et al. demonstrated that the activation of sulfatidereactive CD1d-restricted type II NKT cells ameliorated the experimental murine hepatitis [6] . Terabe et al. showed that CD1d-restricted type II NKT cells were essential for the down-regulation of tumor immunosurveillance in mice [7] . On the other hand, the association of impaired CD1d-restricted type II NKT cells with inflammatory diseases has also been reported. Liao et al. demonstrated that the disordered regulation of CD1d-restricted type II NKT cells could cause spontaneous development of colitis in CD1d transgenic mice [8] . In addition, we have shown that pro-inflammatory autologous vascular endothelial cell-reactive CD1d-restricted type II NKT cells were involved in the development of vasculitis in rats [9] . Recently, we identified P518-532 of rat sterol carrier protein 2 (rSCP2518-532), FFQGKLKIAGNMGLA, as the epitope, which was recognized by one such CD1d-restricted type II NKT cell [10] .
Invariant NKT cells can be detected as CD3-positive α-GalCer-loaded CD1d (α-GalCer/CD1d) multimer-binding cells in flow cytometry [11] [12] [13] . In contrast, CD1drestricted type II NKT cells are less well-characterized due to the lack of a suitable antigen that can substitute for α-GalCer. Hence, we attempted to detect human CD1d-restricted type II NKT cells in peripheral blood using hSCP2518-532, FFQGPLKITGNMGLA, the human counterpart of rSCP2518-532, together with a CD1d tetramer in flow cytometry.
SCP2 is an intracellular protein that is expressed widely in organs and cells involved in lipid metabolism, including the liver and vascular endothelial cells [14] . It also plays a pivotal role in intracellular lipid transfer [15] , which suggests hydrophobicity of SCP2 molecule. On the other hand, CD1d preferably presents hydrophobic antigens. Therefore, it is reasonable to consider that CD1d can present SCP2 peptides.
In this study, we first determined the binding of hSCP2518-532 to CD1d. Next, we detected CD3-positive hSCP2518-532-loaded CD1d (hSCP2518-532/CD1d) tetramerbinding cells in peripheral blood of healthy donors and demonstrated their antiinflammatory property. Furthermore, we compared the prevalence and cytokine profile of SCP2-loaded CD1d (SCP2/CD1d) tetramer-binding type II NKT cells between healthy donors and patients with vasculitis in a pilot study.
MATERIALS AND METHODS

Peripheral blood samples
Upon receiving the written informed consent, 10 ml of peripheral blood was obtained from 8 healthy donors and 5 patients with vasculitis, such as microscopic polyangiitis and Takayasu arteritis ( Table 1 ). All patients with vasculitis were actively suffering from the disease. At the earliest opportunity (within 30 min) after blood sampling, PBMCs were isolated using Ficoll-Paque Plus (GE Healthcare, Tokyo, Japan).
RPMI 1640 medium (Sigma-Aldrich, St. Louis, MO) supplemented with 10% FBS which was used as culture medium. The PBMCs were assayed immediately without being frozen for storage. This study was approved for practice by our institutional ethics committee, the Ethical Committee of the Faculty of Health Sciences, Hokkaido University (Permission No. .
Binding of hSCP2518-532 to CD1d
Human CD1d monomer (molecular mass, 37 kDa) was purchased from Sino Biological (Beijing, China). Amino acid sequence of hSCP2518-532 is FFQGPLKITGNMGLA (molecular mass, <10 kDa). Biotinylated hSCP2518-532 (hSCP2518-532B) was generated by Scrum (Tokyo, Japan). CD1d monomer (100 ng) was incubated with hSCP2518-532B (200 ng) in PBS (10 μl) for 5 h at room temperature. The mixture was then adjusted to 2 ml in PBS and centrifuged at 2,600×g for 30 min using Amicon Ultra 10K (Merck Millipore, Darmstadt, Germany). As controls, samples containing CD1d monomer (100 ng) alone and hSCP2518-532B (200 ng) alone were similarly prepared. The remaining solution (100 µl) after centrifugation was applied to each well of ELISA plates (Sumitomo Bakelite, Tokyo, Japan), and allowed to settle overnight at 4 ºC. The next day, the solution in the wells was removed, and the wells were treated with the blocking solution from a BioLegend ELISA kit (BioLegend, San Diego, CA) per the manufacturer's instruction. Thereafter, avidin-conjugated HRP (50 µl) in the kit was applied to each well. Finally, 3,3',5,5'-tetramethylbenzidine solution (100 µl) was added to the samples, and the reaction was stopped by 2N H2SO4 (100 µl). Absorbance at 450 nm was measured using MALTISKAN FC (Thermo Scientific, Waltham, MA).
Experiments were repeated 3 times independently. Each experiment was conducted in triplicate.
Competition assay
We determined the competitive effects of non-biotinylated hSCP2518-532 and α-GalCer on the binding of hSCP2518-532B to CD1d. CD1d monomer (100 ng) was mixed with hSCP2518-532B (100 ng) alone and together with hSCP2518-532B (100 ng) and nonbiotinylated hSCP2518-532 (100 ng) in PBS (10 μl). Alternatively, prior to incubation of hSCP2518-532B with CD1d, CD1d monomer (100 ng) was mixed overnight with 0, 0.1, 0.5, 1.0, or 2.0 μg of α-GalCer (Funakoshi, Tokyo, Japan) in PBS (15 μl) at room temperature.
The next day, hSCP2518-532B (100 ng) was mixed with the α-GalCer-loaded CD1d (100 ng) in PBS (20 μl). After incubation for 5 h at room temperature, the mixture was adjusted to 2 ml in PBS and centrifuged at 2,600×g for 30 min using Amicon Ultra 10K. The remaining solution (100 µl) expected to contain bound antigens, including hSCP2518-532B, was applied to each well of ELISA plates, and color development was conducted as 
Detection of SCP2/CD1d tetramer-binding type II NKT cells in flow cytometry
APC-conjugated human CD1d tetramer was purchased from Medical & Biological Laboratory (Nagoya, Japan). One hundred ng of hSCP2518-532 and a different peptide hSCP2526-540, TGNMGLAMKLQNLQL (generated by Scrum), as control were independently mixed overnight with 10 μl of the CD1d tetramer at room temperature as previously described [5] . The next day, PBMCs (1 × 10 6 ) were stained with 20 µl of PEconjugated anti-human CD3 antibody (UCHT-1, mouse IgG1κ) (BD Pharmingen, Franklin Lakes, NJ) for 30 min on ice. After washing with PBS, the cells were stained with the APC-conjugated CD1d tetramer without antigen-loading or APC-conjugated SCP2/CD1d tetramer, for 30 min on ice (total volume, 100 μl) according to the instruction provided from the reagent manufacturer. After washing with PBS, the cells were analyzed using FACS Canto II (BD Biosciences, Tokyo, Japan) and data was processed by FACSDiva software ver. 7.0 (BD Biosciences). In some experiments, PBMCs were stained with PerCP-conjugated anti-TCR Vα24-Jα18 antibody (6B11, mouse IgG1κ) (Thermo Fisher Scientific, Yokohama, Japan) together with the PE-conjugated anti-CD3 antibody and APC-conjugated hSCP2518-532/CD1d tetramer.
Cytokine profiling
PBMCs were adjusted to 2.5 × 10 6 /ml in the culture medium and stimulated with the PE-conjugated anti-human CD3 antibody (20 μl/1 × 10 6 cells) and anti-human 
Statistics
The Student's t-test was applied for comparison of the mean values between the two groups in the CD1d binding assay. The Mann-Whitney U-test was applied for comparison of the two groups in flow cytometry. A p-value of less than 0.05 was considered statistically significant.
RESULTS
Binding of hSCP2518-532 to CD1d
Initially, we determined the binding of hSCP2518-532 to CD1d using hSCP2518-532B (Fig. 1a) . For this purpose, CD1d monomer (molecular mass, 37 kDa) and hSCP2518-532B (molecular mass, <10 kDa) were mixed in PBS and then centrifuged to filter through a 10-kDa pore size. We hypothesized that the remaining solution after centrifugation would contain CD1d/hSCP2518-532B complexes, as well as unbound CD1d, but no free The binding of 100 ng of hSCP2518-532B to 100 ng of CD1d was significantly inhibited by the competition with 100 ng of non-biotinylated hSCP2518-532 or more than 1 µg of α-GalCer (Fig. 1b) . The 50% inhibition of the hSCP2518-532B binding to CD1d by an identical dose of non-biotinylated hSCP2518-532 is reasonable. In addition, the reduction was dependent on the dose of α-GalCer that competed with hSCP2518-532B.
Detection of SCP2/CD1d tetramer-binding type II NKT cells in flow cytometry
We detected CD3-positive hSCP2518-532/CD1d tetramer-binding type II NKT cells in peripheral blood of healthy donors using flow cytometry. When we used CD1d tetramer without peptide-loading and with a different SCP2 peptide hSCP2526-540, TGNMGLAMKLQNLQL, as control, these probes hardly bound to CD3-positive T cells.
On the contrary, a few of CD3-positive cells bound to the hSCP2518-532/CD1d tetramer ( Fig. 2a) . Since the CD3-positive hSCP2518-532/CD1d tetramer-binding cells did not express the iNKT-specific TCR Vα24-Jα18 (Fig. S1) , the possibility of these cells as iNKT cells could be ruled out. The percentage of hSCP2518-532/CD1d tetramer-binding cells (SCP2/CD1d tetramer-binding type II NKT cells) in CD3-positive T cells ranged from 0.27% to 0.58% in healthy individuals (0.43 ± 0.16%). Interestingly, the percentage was significantly higher in vasculitic patients (1.57 ± 0.74%) than in the healthy controls (p<0.05) ( Figs. 2b and 2c) .
Cytokine profiling of SCP2/CD1d tetramer-binding type II NKT cells
To verify the anti-inflammatory property of SCP2/CD1d tetramer-binding type II NKT cells, PBMCs of healthy donors were stimulated using anti-CD3 and anti-CD28 antibodies. The cytokine profile of these cells was determined. For this purpose, TNF-α and TGF-β were used as representatives of pro-inflammatory and anti-inflammatory cytokines, respectively. As shown in Fig. 3a , there were greater numbers of TGF-βproducing cells compared to TNF-α-producing cells in SCP2/CD1d tetramer-binding type II NKT cells of healthy donors. Although the data exhibit a whole shift of TGF-β staining, which could reflect a non-specific binding of the antibody to TGF-β-negative cells, our titration study suggested that the dose of the antibody (5 μl/sample) was acceptable (Fig.   S2 ). These findings are consistent with the anti-inflammatory property of CD1d-restricted type II NKT cells.
When we assayed T cells without binding to the hSCP2518-532/CD1d tetramer and type I NKT (iNKT) cells (CD3-positive α-GalCer/CD1d tetramer-binding cells), such characteristics were not noted ( Figs. S3 and S4, respectively) . To exclude the putative artifact caused by dead cells in this assay, we utilized LIVE/DEAD fixable dead cell stain kit in our experiments. Since there was no significant difference in the results regardless of the presence of dead cells in samples, it was considered that the hSCP2518-532/CD1d tetramer did not exhibit non-specific binding to dead cells (data not shown).
Lastly, we compared the cytokine profile between healthy donors (n=8) and patients with vasculitis (n=5), such as microscopic polyangiitis and Takayasu arteritis ( Figs. 3b and 3c) . All patients with vasculitis were actively suffering from the disease.
The percentage of TGF-β-producing cells in SCP2/CD1d tetramer-binding type II NKT cells was significantly lower in vasculitic patients than in healthy controls (p<0.05).
DISCUSSION
CD1d-restricted NKT cells are classified into type I and type II subsets [2] . The type I subset is defined by a conserved expression of TCR α-chain (Vα24-Jα18 in humans and Vα14-Jα18 in rodents), whereas type II subsets have a more variable TCR repertoire.
The physiological roles of these cells can be assessed using Jα18-deficient mice, which specifically lack the type I subset, and CD1d-deficient mice, which lack both type I and type II subsets [16] . The roles of CD1d-restricted type II NKT cells can be speculated by the difference between Jα18-deficient mice and CD1d-deficient mice. However, a technically sound method to detect human CD1d-restricted type II NKT cells has not been established.
Although the optimized multicolor immunofluorescence panels to identify human NK cells have been published [17] [18] [19] [20] , an attempt to detect CD1d-restricted type II NKT cells without sorting NK cells is still challenging. Recent studies have revealed that these cells could recognize a kind of sphingophospholipid sulfatide, which is abundant in the myelin sheaths of the central nervous system [21] . Based on this evidence, sulfatide-loaded CD1d tetramer has been initially used to detect CD1d-restricted type II NKT cells. However, this approach is limited due to the difficulty in the preparation of ligand-loaded CD1d tetramers to detect CD1d-restricted type II NKT cells specifically.
Hence, the development of a new strategy to detect CD1d-restricted type II NKT is required.
In our earlier study, we identified rSCP2518-532, FFQGKLKIAGNMGLA, as the epitope, which was recognized by one of rat CD1d-restricted type II NKT cells [10] . In this study, we attempted to detect human CD1d-restricted type II NKT cells in peripheral blood using hSCP2518-532, FFQGPLKITGNMGLA, the human counterpart of rSCP2518-532, together with a CD1d tetramer in flow cytometry.
In the beginning of this study, we determined the binding of hSCP2518-532 to CD1d. Since there was competitive binding with α-GalCer, we thought that hSCP2518-532 could be presented by CD1d adequately. Even though α-GalCer competed with hSCP2518-532B more than 10 times, the effect was still limited. This may reflect the difference in the binding formation of peptide-CD1d and glycolipid-CD1d. X-ray analyses have demonstrated that peptides can bind into the cleft between the α1 and α2 helixes of CD1d like the binding to MHC. Whereas glycolipids, such as α-GalCer, deeply penetrate A' and F' pockets of CD1d [22] . There is still another possibility of the higher affinity of hSCP2518-532 than α-GalCer to CD1d.
Next, we detected SCP2/CD1d tetramer-binding type II NKT cells in peripheral blood of healthy donors and noted that its prevalence in vasculitic patients was significantly higher than in healthy donors. We also noted the anti-inflammatory property of SCP2/CD1d tetramer-binding type II NKT cells but not α-GalCer/CD1d tetramerbinding type I NKT (iNKT) cells in healthy donors. The comparison of cell surface markers between SCP2/CD1d tetramer-binding type II NKT cells and iNKT cells has not yet been completed. These are critical tasks in our future studies.
Since the antigen-presenting molecule CD1d can present diverse hydrophobic antigens, there seems to be diversity among CD1d-restricted type II NKT cells. Although it is expected that these heterogeneous CD1d-restricted type II NKT cells assist in regulating inflammation, further studies are needed to determine if they can react with antigens other than SCP2 and also exhibit an anti-inflammatory property.
It remains unclear whether the decrease in rate of TGF-β-producing cells in SCP2/CD1d tetramer-binding type II NKT cells is a cause or a result of vasculitis.
Concerning this issue, we examined the cytokine profile of SCP2/CD1d tetramer-binding type II NKT cells obtained from one of the vasculitic patients who started to experience remission after treatment. Remarkably, in this patient, the rate of TGF-β-producing cells in SCP2/CD1d tetramer-binding type II NKT cells was comparable to the control level (unpublished results). Although further studies are needed, we believe that the reduced TGF-β production of SCP2/CD1d tetramer-binding type II NKT cells in patients with active vasculitis may be a result of the disease and, therefore, reversible.
There are some critical limitations in this study. First, we have to note the disparity in age between the vasculitic patients and healthy controls. Second, most data presented in this manuscript were obtained from samples containing dead cells. Although we have confirmed that there is no significant difference in the results regardless of the presence of dead cells in samples, using the LIVE/DEAD fixable dead cell stain kit, we have to improve the protocol in our future studies. Third, the percentage of SCP2/CD1d tetramer-binding type II NKT cells in peripheral blood is very small. Therefore, we have to pay particular attention to avoid measuring noise. Especially, we have to realize the possibility of an overestimation for the rates of TGF-β-expressing cells. Further studies will be crucial to confirm our findings.
This pilot study demonstrates the practicability of detection and cytokine profiling of SCP2/CD1d tetramer-binding type II NKT cells in peripheral blood with a limited sample of patients. Although further studies are needed to clarify the pathogenic role of SCP2/CD1d tetramer-binding type II NKT cells, these cells in peripheral blood should be examined in more detail for better understanding of the pathophysiology of vasculitides in humans. Moreover, recent reviews on type II NKT cells suggest the critical involvement of the cells in microbial immunity, inflammation, autoimmunity, and cancer [23, 24] . The method to detect autoreactive type II NKT cells could be applicable to investigate the pathophysiology of diverse diseases as well as vasculitides.
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